• 52,754+ CME Conference Registrations Sold
  • 158,262+ Medical Conferences
  • 285 Specialties
  • 11,425 Organizers
  • 157,177 Speakers
  • 159 Countries
  • 4,803 Cities

SEARCH NEWS
Or

DPP-4 Inhibitor Has Dissociated Effects on β-Cell Function

DPP-4 Inhibitor Has Dissociated Effects on β-Cell Function

Wed, Dec 20, 2017

WEDNESDAY, Dec. 20, 2017 (HealthDay News) -- For healthy adults and individuals with well-controlled type 2 diabetes (T2D), a single dose of the dipeptidyl peptidase-4 inhibitor sitagliptin is associated with increased standardized insulin secretion, with no impact on β-cell glucose sensitivity, according to a study published online Dec. 11 in Diabetes, Obesity and Metabolism.

Wathik Al Salim, M.D., from Lund University in Sweden, and colleagues examined the effects of a single dose of sitagliptin on glucose-standardized insulin secretion and β-cell sensitivity after meal ingestion. Twelve healthy and 12 drug-naive subjects with well-controlled T2D received sitagliptin or placebo before a meal.

The researchers found that, compared with placebo, sitagliptin was correlated with increased standardized insulin secretion in healthy and T2D subjects without increasing β-cell glucose sensitivity. Increases in active glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) were also seen with sitagliptin, as were decreases in total GIP but not total GLP-1 levels.

"We conclude that a single dose of DPP-4 inhibition induces dissociated effects on different aspects of β-cell function and incretin hormones after meal ingestion in healthy subjects and in well-controlled T2D," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Convert
Live to Virtual Conference

Market your online event to Million plus Healthcare professionals.